JP4717633B2 - 癌関連タンパク質を標的とするＲＮＡｉプローブ - Google Patents

癌関連タンパク質を標的とするＲＮＡｉプローブ Download PDF

Info

Publication number
JP4717633B2
JP4717633B2 JP2005501198A JP2005501198A JP4717633B2 JP 4717633 B2 JP4717633 B2 JP 4717633B2 JP 2005501198 A JP2005501198 A JP 2005501198A JP 2005501198 A JP2005501198 A JP 2005501198A JP 4717633 B2 JP4717633 B2 JP 4717633B2
Authority
JP
Japan
Prior art keywords
seq
cells
clu
sirna
clusterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2005501198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500958A5 (https=
JP2006500958A (ja
Inventor
ヤンセン、バークハード
グリーブ、マーティン、イー．
シグナエブスキー、マクシム
ベラルディ、エリアナ
トルガコス、イオアニス、ピー．
ゴノス、エフスタシオス、エス．
Original Assignee
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア filed Critical ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Publication of JP2006500958A publication Critical patent/JP2006500958A/ja
Publication of JP2006500958A5 publication Critical patent/JP2006500958A5/ja
Application granted granted Critical
Publication of JP4717633B2 publication Critical patent/JP4717633B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2005501198A 2002-08-21 2003-08-21 癌関連タンパク質を標的とするＲＮＡｉプローブ Expired - Fee Related JP4717633B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US60/405,193 2002-08-21
US40815202P 2002-09-03 2002-09-03
US60/408,152 2002-09-03
US47238703P 2003-05-20 2003-05-20
US60/472,387 2003-05-20
PCT/CA2003/001277 WO2004018676A2 (en) 2002-08-21 2003-08-21 Rnai probes targeting cancer-related proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010128382A Division JP5171887B2 (ja) 2002-08-21 2010-06-04 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010250838A Division JP5662766B2 (ja) 2002-08-21 2010-11-09 癌関連タンパク質を標的とするＲＮＡｉプローブ

Publications (3)

Publication Number Publication Date
JP2006500958A JP2006500958A (ja) 2006-01-12
JP2006500958A5 JP2006500958A5 (https=) 2006-09-07
JP4717633B2 true JP4717633B2 (ja) 2011-07-06

Family

ID=31950539

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2005501198A Expired - Fee Related JP4717633B2 (ja) 2002-08-21 2003-08-21 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010128382A Expired - Fee Related JP5171887B2 (ja) 2002-08-21 2010-06-04 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010250838A Expired - Fee Related JP5662766B2 (ja) 2002-08-21 2010-11-09 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2013067754A Pending JP2013150624A (ja) 2002-08-21 2013-03-28 癌関連タンパク質を標的とするＲＮＡｉプローブ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010128382A Expired - Fee Related JP5171887B2 (ja) 2002-08-21 2010-06-04 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010250838A Expired - Fee Related JP5662766B2 (ja) 2002-08-21 2010-11-09 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2013067754A Pending JP2013150624A (ja) 2002-08-21 2013-03-28 癌関連タンパク質を標的とするＲＮＡｉプローブ

Country Status (10)

Country Link
US (5) US8252918B2 (https=)
EP (2) EP1532249A2 (https=)
JP (4) JP4717633B2 (https=)
KR (3) KR101117673B1 (https=)
AU (1) AU2003258426B2 (https=)
CA (2) CA2494766C (https=)
IL (3) IL166658A (https=)
NO (2) NO334573B1 (https=)
NZ (1) NZ552872A (https=)
WO (1) WO2004018676A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011036267A (ja) * 2002-08-21 2011-02-24 Univ Of British Columbia 癌関連タンパク質を標的とするＲＮＡｉプローブ

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2003237616B2 (en) * 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
NZ538288A (en) * 2002-08-21 2008-04-30 Univ British Columbia Treatment of melanoma by reduction in clusterin levels
EP1615658A1 (en) 2003-03-25 2006-01-18 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
US20050019918A1 (en) * 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
BRPI0508970A (pt) * 2004-03-19 2007-08-21 Penn State Res Found método combinatórios e composições para o tratamento de melanoma
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
JP4852539B2 (ja) * 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
EP1784503A4 (en) * 2004-07-23 2009-08-12 Pacific Edge Biotechnology Ltd URINMARKER FOR THE DETECTION OF BUBBLE CANCER
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
WO2008088836A2 (en) * 2007-01-16 2008-07-24 The Burnham Institute For Medical Research Compositions and methods for treatment of colorectal cancer
US8071752B2 (en) 2007-01-29 2011-12-06 City Of Hope Multi-targeting short interfering RNAs
WO2008109361A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc, Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US8217161B2 (en) * 2008-04-22 2012-07-10 Clemson University Research Foundation Methods of inhibiting multiple cytochrome P450 genes with siRNA
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
ES2645366T3 (es) 2011-02-11 2017-12-05 The Rockefeller University Tratamiento de trastornos de la angiogénesis
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
CN106282185B (zh) * 2016-08-18 2020-06-26 广州市锐博生物科技有限公司 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用
KR102923964B1 (ko) * 2023-04-13 2026-02-09 한양대학교 에리카산학협력단 Igfbp5 돌연변이체 또는 이를 발현하는 벡터를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
WO2024214933A1 (ko) * 2023-04-13 2024-10-17 한양대학교 에리카산학협력단 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
WO2025041340A1 (ja) * 2023-08-24 2025-02-27 株式会社Dti 二重特異性核酸

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736580A (en) * 1980-08-13 1982-02-27 Hitachi Ltd Protecting method for converter
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20020086386A1 (en) * 1997-03-04 2002-07-04 Kamb Carl Alexander B-catenin assays, and compositions therefrom
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
CA2375467C (en) * 1999-07-19 2013-10-29 The University Of British Columbia Antisense therapy for hormone-regulated tumors
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
AU2001290920B2 (en) 2000-09-14 2006-11-23 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
JP4717633B2 (ja) * 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするＲＮＡｉプローブ
NZ538288A (en) * 2002-08-21 2008-04-30 Univ British Columbia Treatment of melanoma by reduction in clusterin levels
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011036267A (ja) * 2002-08-21 2011-02-24 Univ Of British Columbia 癌関連タンパク質を標的とするＲＮＡｉプローブ

Also Published As

Publication number Publication date
EP2263679A3 (en) 2011-10-12
AU2003258426A1 (en) 2004-03-11
IL166658A (en) 2014-11-30
US9487777B2 (en) 2016-11-08
US20120202873A1 (en) 2012-08-09
IL233352A0 (en) 2014-08-31
NO334573B1 (no) 2014-04-14
JP2013150624A (ja) 2013-08-08
JP2011036267A (ja) 2011-02-24
NO337130B1 (no) 2016-01-25
US20060178329A1 (en) 2006-08-10
WO2004018676A3 (en) 2004-08-12
EP2263679B1 (en) 2014-10-08
NO20051423L (no) 2005-05-20
JP5171887B2 (ja) 2013-03-27
JP5662766B2 (ja) 2015-02-04
AU2003258426B2 (en) 2008-04-10
CA2494766C (en) 2015-05-12
US20110009472A1 (en) 2011-01-13
WO2004018676A2 (en) 2004-03-04
US8252918B2 (en) 2012-08-28
CA2494766A1 (en) 2004-03-04
KR20100135335A (ko) 2010-12-24
KR101212512B1 (ko) 2012-12-26
CA2882443A1 (en) 2004-03-04
US7964717B2 (en) 2011-06-21
KR101117673B1 (ko) 2012-03-07
US7820635B2 (en) 2010-10-26
CA2882443C (en) 2016-12-13
NO20121038L (no) 2005-05-20
IL197159A (en) 2016-11-30
EP2263679A2 (en) 2010-12-22
KR20050042483A (ko) 2005-05-09
JP2006500958A (ja) 2006-01-12
IL166658A0 (en) 2006-01-15
KR101238701B1 (ko) 2013-03-05
US8759308B2 (en) 2014-06-24
KR20110122883A (ko) 2011-11-11
NZ552872A (en) 2007-11-30
US20080274996A1 (en) 2008-11-06
US20040096882A1 (en) 2004-05-20
JP2010193908A (ja) 2010-09-09
EP1532249A2 (en) 2005-05-25
IL197159A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
JP5171887B2 (ja) 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP5841332B2 (ja) 細胞増殖阻害剤
CA3161513A1 (en) Antisense oligonucleotide targeting linc00518 for treating melanoma
AU2007216630B2 (en) RNAi probes targeting cancer-related proteins
NZ538287A (en) RNAi probes targeting cancer-related proteins
CA2680058C (en) Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
US20170044548A1 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110330

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees